Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2096245 | 0.94 | KIF11 (0.49) | MAOBALDH1A1AOC3 | |
| SCHEMBL7751885 | 0.94 | LTA4H (0.53) | MAOBALDH1A1AOC3LTA4H | |
| SCHEMBL1044973 | 0.83 | LTA4H (0.50) | MAOBALDH1A1AOC3LTA4HNOS1 | |
| SCHEMBL1046760 | 0.81 | NOS1 (0.50) | MAOBALDH1A1AOC3LTA4HNOS1 | |
| SCHEMBL4707838 | 0.80 | NQO1 (0.47) | MAOBLTA4HCA1CA2CA9 | |
| SCHEMBL1047648 | 0.79 | NOS1 (0.51) | MAOBALDH1A1AOC3LTA4HNOS1 | |
| SCHEMBL8778626 | 0.78 | NOS1 (0.52) | MAOBALDH1A1AOC3LTA4HNOS1 | |
| SCHEMBL1046516 | 0.78 | NOS1 (0.52) | MAOBALDH1A1AOC3LTA4HNOS1 | |
| SCHEMBL2099230 | 0.77 | ALDH1A1 (0.53) | MAOBALDH1A1AOC3LTA4HCA1 | |
| SCHEMBL2099227 | 0.77 | ALDH1A1 (0.53) | MAOBALDH1A1AOC3LTA4HCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113501774-B | Method for synthesizing bromodifluoromethyl selenide compounds under metal-free condition | 江苏省原子医学研究所 | 2023-02-28 | — | — | CN | claimed |
| CN-113501774-A | Method for synthesizing bromodifluoromethyl selenide compounds under metal-free condition | 江苏省原子医学研究所 | 2021-10-15 | — | — | CN | claimed |
| US-20240182463-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2024-06-06 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230117695-A1 | ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2023-04-20 | — | — | US | disclosed |
| CN-113501774-B | Method for synthesizing bromodifluoromethyl selenide compounds under metal-free condition | 江苏省原子医学研究所 | 2023-02-28 | — | — | CN | disclosed |
| US-11492352-B2 | Arenavirus growth inhibitor comprising polycyclic carbamoylpyridone derivative | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2022-11-08 | — | — | US | disclosed |
| CN-113501774-A | Method for synthesizing bromodifluoromethyl selenide compounds under metal-free condition | 江苏省原子医学研究所 | 2021-10-15 | — | — | CN | disclosed |
| US-20210292321-A1 | ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2021-09-23 | — | — | US | disclosed |
| US-5086071-A | Improved chemical stability and ppotent in vivo | TORAY INDUSTRIES, INC. (JP) | 1992-02-04 | — | — | US | disclosed |
| EP-0232776-B1 | 2,5,6,7-TETRANOR-4,8-INTER-M-PHENYLENE PGI2 DERIVATIVES | TORAY INDUSTRIES, INC. (JP) | 1990-10-24 | — | — | EP | disclosed |
| EP-0389162-A1 | 2,5,6,7-Tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1990-09-26 | — | — | EP | disclosed |
| EP-0365678-A1 | 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLENE PGI 2 DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1990-05-02 | — | — | EP | disclosed |
| US-4775692-A | ANTILIPEMIC, ANTICOAGULANT, HYPOTENSIVE, ANTISECRETORY AND ANTIULCER AGENT | TORAY INDUSTRIES, INC. (JP) | 1988-10-04 | — | — | US | disclosed |
| EP-0232776-A2 | 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1987-08-19 | — | — | EP | disclosed |
| US-4599335-A | FUNGICIDES, BACTERICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1986-07-08 | — | — | US | disclosed |
| EP-0026004-B1 | LIQUID CRYSTALS MIXTURE | BBC Aktiengesellschaft Brown, Boveri & Cie. (CH) | 1983-05-18 | — | — | EP | disclosed |
| EP-0026004-A1 | Liquid crystals mixture | BBC Aktiengesellschaft Brown, Boveri & Cie. (CH) | 1981-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492352-B2 | Arenavirus growth inhibitor comprising polycyclic carbamoylpyridone derivative | LUC7L2, CXCR6, RRP12 | MAOB 3618/4885ALDH1A1 4161/4885AOC3 2816/4885 |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MAOB 4852/4885ALDH1A1 4838/4885AOC3 4747/4885 |
| US-20240182463-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | MAOB 694/4885ALDH1A1 1564/4885AOC3 2280/4885 |
| US-20230117695-A1 | ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | CDK7, CCNA1, CCR10 | MAOB 2986/4885ALDH1A1 4215/4885AOC3 2535/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | MAOB 4620/4885ALDH1A1 4861/4885AOC3 4791/4885 |
| US-20210292321-A1 | ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | CCNA1, CDK7, CCR10 | MAOB 2966/4885ALDH1A1 4074/4885AOC3 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.